Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response

Antoine G. van der Heijden; Paula M. J. Moonen; Erik B. Cornel; Henk Vergunst; Theo M. de Reijke; Erika van Boven; Evert J. Barten; Rajiv Puri; Coenraad K. van Kalken; J. Alfred Witjes

doi:https://doi.org/10.1016/j.juro.2006.06.007

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response

Antoine G. van der Heijden, Paula M. J. Moonen, Erik B. Cornel, Henk Vergunst, Theo M. de Reijke, Erika van Boven, Evert J. Barten, Rajiv Puri, Coenraad K. van Kalken, J. Alfred Witjes

Research output: Contribution to journal › Article › Academic › peer-review

60 Citations (Scopus)

Abstract

We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. A total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. One patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. The histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations

Original language	English
Pages (from-to)	1349-53; discussion 1353
Journal	Journal of urology
Volume	176
Issue number	4 Part 1
DOIs	https://doi.org/10.1016/j.juro.2006.06.007
Publication status	Published - 2006

Access to Document

https://doi.org/10.1016/j.juro.2006.06.007

Cite this

van der Heijden, A. G., Moonen, P. M. J., Cornel, E. B., Vergunst, H., de Reijke, T. M., van Boven, E., Barten, E. J., Puri, R., van Kalken, C. K., & Witjes, J. A. (2006). Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. Journal of urology, 176(4 Part 1), 1349-53; discussion 1353. https://doi.org/10.1016/j.juro.2006.06.007

@article{b43a7196ff1144b78cec1fde82c96cbf,

title = "Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response",

abstract = "We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. A total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. One patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. The histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations",

author = "{van der Heijden}, {Antoine G.} and Moonen, {Paula M. J.} and Cornel, {Erik B.} and Henk Vergunst and {de Reijke}, {Theo M.} and {van Boven}, Erika and Barten, {Evert J.} and Rajiv Puri and {van Kalken}, {Coenraad K.} and Witjes, {J. Alfred}",

year = "2006",

doi = "https://doi.org/10.1016/j.juro.2006.06.007",

language = "English",

volume = "176",

pages = "1349--53; discussion 1353",

journal = "Journal of urology",

issn = "0022-5347",

publisher = "Elsevier Inc.",

number = "4 Part 1",

}

van der Heijden, AG, Moonen, PMJ, Cornel, EB, Vergunst, H, de Reijke, TM, van Boven, E, Barten, EJ, Puri, R, van Kalken, CK & Witjes, JA 2006, 'Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response', Journal of urology, vol. 176, no. 4 Part 1, pp. 1349-53; discussion 1353. https://doi.org/10.1016/j.juro.2006.06.007

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. / van der Heijden, Antoine G.; Moonen, Paula M. J.; Cornel, Erik B. et al.
In: Journal of urology, Vol. 176, No. 4 Part 1, 2006, p. 1349-53; discussion 1353.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response

AU - van der Heijden, Antoine G.

AU - Moonen, Paula M. J.

AU - Cornel, Erik B.

AU - Vergunst, Henk

AU - de Reijke, Theo M.

AU - van Boven, Erika

AU - Barten, Evert J.

AU - Puri, Rajiv

AU - van Kalken, Coenraad K.

AU - Witjes, J. Alfred

PY - 2006

Y1 - 2006

N2 - We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. A total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. One patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. The histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations

AB - We studied the ablative activity of intravesical apaziquone (EOquin) on a papillary marker tumor and determined the incidence of side effects. A total of 46 patients with multiple pTa or pT1 bladder tumors underwent visible lesion resection except for 1 marker tumor. Patients were then treated with 6 instillations of apaziquone at weekly intervals. The response was determined 2 to 4 weeks after the last instillation. One patient withdrew informed consent and refused the last treatment due to side effects. A histologically proven complete response was seen in 30 patients. Progression to invasive stage was not observed. Local side effects in this study were comparable to those due to other chemotherapy instillations, such as mitomycin C and epirubicin, but less severe and less frequent compared to those of bacillus Calmette-Guerin instillations. The histological complete response rate after 6 consecutive instillations of apaziquone in patients with superficial bladder cancer was 67% (95% CI 51 to 80). Local side effects were comparable to side effects due to other chemotherapy instillations

U2 - https://doi.org/10.1016/j.juro.2006.06.007

DO - https://doi.org/10.1016/j.juro.2006.06.007

M3 - Article

C2 - 16952629

SN - 0022-5347

VL - 176

SP - 1349-53; discussion 1353

JO - Journal of urology

JF - Journal of urology

IS - 4 Part 1

ER -